KeyBioscience AG
Lugano, CH· latest recorded location
KeyBioscience AG is named on 8 US grants and 11 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 8
- Published applications
- 11
- Inventors
- 14
- Granted in 2026 so far
- 1
- Most recent grant
- 17 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 1 | 1 |
| 2016 | 1 | 1 |
| 2017 | 1 | 2 |
| 2018 | 1 | 2 |
| 2019 | 3 | 2 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 19 documents
Recent patents
- Dual amylin and calcitonin receptor agonists and uses thereof17 Feb 2026US 12,551,566 B2
- Calcitonin analogues for treating diseases and disorders16 Jul 2019US 10,350,272 B2
- Peptide analogs for treating diseases and disorders26 Mar 2019US 10,239,929 B2
- Calcitonin mimetics for treating diseases and disorders19 Mar 2019US 10,232,021 B2
- Peptide analogs for treating diseases and disorders9 Jan 2018US 9,862,754 B2
- Fibroblast Activation Markers and TGFBI in Therapy3 Sep 2026US 2026/0258118 A1
- Acylated Calcitonin Mimetics1 Dec 2022US 2022/0380432 A1
- Calcitonin Mimetics for Treating Diseases and Disorders25 Jun 2020US 2020/0199190 A1
- Calcitonin Analogues for Treating Diseases and Disorders31 Oct 2019US 2019/0328843 A1
- Calcitonin Mimetics for Treating Diseases and Disorders16 May 2019US 2019/0142903 A1
Most cited
By later US patents